Directorio de personas
Joan Valls Marsal

Joan Valls Marsal

Grado: Doctor/a

28 02
joan.valls(ELIMINAR)@udl.cat

ResearcherID: https://www.researcherid.com/rid/GXM-6532-2022

OrcidID: https://orcid.org/0000-0002-4806-7568

Grupos

Publicaciones

  • Pujana MA; Ruiz A; Badenas C; Puig-Butille JA; Nadal M; Stark M; Gómez L; Valls J; Solé X; Hernández P; Cerrato C; Madrigal I; de Cid R; Aguilar H; Capellá G; Cal S; James MR; Walker GJ; Malvehy J; Milà M; Hayward NK; Estivill X; Puig S

    Molecular characterization of a t(9;12)(p21;q13) balanced chromosome translocation in combination with integrative genomics analysis identifies C9orf14 as a candidate tumor-suppressor.

    GENES CHROMOSOMES & CANCER 46 155-162. .

    [doi:10.1002/gcc.20396]

  • Pros E; Larriba S; López E; Ravella A; Gili ML; Kruyer H; Valls J; Serra E; Lázaro C

    NF1 mutation rather than individual genetic variability is the main determinant of the NF1-transcriptional profile of mutations affecting splicing.

    HUMAN MUTATION 27 1104-1114. .

    [doi:10.1002/humu.20396]

  • Solé X; Guinó E; Valls J; Iniesta R; Moreno V

    SNPStats: a web tool for the analysis of association studies.

    BIOINFORMATICS 22 1928-1929. .

    [doi:10.1093/bioinformatics/btl268]

  • Montaner D; Tárraga J; Huerta-Cepas J; Burguet J; Vaquerizas JM; Conde L; Minguez P; Vera J; Mukherjee S; Valls J; Pujana MA; Alloza E; Herrero J; Al-Shahrour F; Dopazo J

    Next station in microarray data analysis: GEPAS.

    NUCLEIC ACIDS RESEARCH 34 -. .

    [doi:10.1093/nar/gkl197]

  • Nakuci E; Xu M; Pujana MA; Valls J; Elshamy WM

    Geminin is bound to chromatin in G2/M phase to promote proper cytokinesis.

    INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY 38 1207-1220. .

    [doi:10.1016/j.biocel.2005.12.017]

  • Grau M; Solé X; Obrador A; Tarafa G; Vendrell E; Valls J; Moreno V; Peinado MA; Capellá G

    Validation of RNA arbitrarily primed PCR probes hybridized to glass cDNA microarrays: application to the analysis of limited samples.

    CLINICAL CHEMISTRY 51 93-101. .

    [doi:10.1373/clinchem.2004.036236]

Proyectos

  • Effects of intravenous iron therapy with ferric carboxymaltose compared with oral iron therapy in heart failure with preserved ejection fraction and iron deficency/ Efecto sobre la capacidad funcional del tratamiento con hierro intravenoso o hierro oral, comparado con placebo, en pacientes con insuficiencia cardiaca con fracción de eyección del ventrículo izquierdo preservada y anemia ferropénica
  • Genomic approach for individualizing endometrial cancer diagnosis, prognosis and treatment
  • VALIDACION DE ANEXINA 2 COMO PREDICTOR DE RECIDIVA EN EL CANCER DE ENDOMETRIO. DISEÑO DE NUEVAS ESTRATEGIAS TERAPEUTICAS. ANXARECU